Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1

O. Babosova, K. Kapralova, L. Raskova Kafkova, V. Korinek, V. Divoky, JT. Prchal, L. Lanikova,

. 2019 ; 23 (11) : 7785-7795. [pub] 20190913

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025541

Grant support
NV16-31689A MZ0 CEP Register

The patients with mantle cell lymphoma (MCL) have translocation t(11;14) associated with cyclin D1 overexpression. We observed that iron (an essential cofactor of dioxygenases including prolyl hydroxylases [PHDs]) depletion by deferoxamine blocked MCL cells' proliferation, increased expression of DNA damage marker γH2AX, induced cell cycle arrest and decreased cyclin D1 level. Treatment of MCL cell lines with dimethyloxalylglycine, which blocks dioxygenases involving PHDs by competing with their substrate 2-oxoglutarate, leads to their decreased proliferation and the decrease of cyclin D1 level. We then postulated that loss of EGLN2/PHD1 in MCL cells may lead to down-regulation of cyclin D1 by blocking the degradation of FOXO3A, a cyclin D1 suppressor. However, the CRISPR/Cas9-based loss-of-function of EGLN2/PHD1 did not affect cyclin D1 expression and the loss of FOXO3A did not restore cyclin D1 levels after iron chelation. These data suggest that expression of cyclin D1 in MCL is not controlled by ENGL2/PHD1-FOXO3A pathway and that chelation- and 2-oxoglutarate competition-mediated down-regulation of cyclin D1 in MCL cells is driven by yet unknown mechanism involving iron- and 2-oxoglutarate-dependent dioxygenases other than PHD1. These data support further exploration of the use of iron chelation and 2-oxoglutarate-dependent dioxygenase inhibitors as a novel therapy of MCL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025541
003      
CZ-PrNML
005      
20220512081850.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcmm.14655 $2 doi
035    __
$a (PubMed)31517438
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Babosova, Olga $u Department of Cell and Developmental Biology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
245    10
$a Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1 / $c O. Babosova, K. Kapralova, L. Raskova Kafkova, V. Korinek, V. Divoky, JT. Prchal, L. Lanikova,
520    9_
$a The patients with mantle cell lymphoma (MCL) have translocation t(11;14) associated with cyclin D1 overexpression. We observed that iron (an essential cofactor of dioxygenases including prolyl hydroxylases [PHDs]) depletion by deferoxamine blocked MCL cells' proliferation, increased expression of DNA damage marker γH2AX, induced cell cycle arrest and decreased cyclin D1 level. Treatment of MCL cell lines with dimethyloxalylglycine, which blocks dioxygenases involving PHDs by competing with their substrate 2-oxoglutarate, leads to their decreased proliferation and the decrease of cyclin D1 level. We then postulated that loss of EGLN2/PHD1 in MCL cells may lead to down-regulation of cyclin D1 by blocking the degradation of FOXO3A, a cyclin D1 suppressor. However, the CRISPR/Cas9-based loss-of-function of EGLN2/PHD1 did not affect cyclin D1 expression and the loss of FOXO3A did not restore cyclin D1 levels after iron chelation. These data suggest that expression of cyclin D1 in MCL is not controlled by ENGL2/PHD1-FOXO3A pathway and that chelation- and 2-oxoglutarate competition-mediated down-regulation of cyclin D1 in MCL cells is driven by yet unknown mechanism involving iron- and 2-oxoglutarate-dependent dioxygenases other than PHD1. These data support further exploration of the use of iron chelation and 2-oxoglutarate-dependent dioxygenase inhibitors as a novel therapy of MCL.
650    _2
$a aminokyseliny dikarboxylové $x farmakologie $7 D000600
650    _2
$a hypoxie buňky $x účinky léků $7 D015687
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cyklin D1 $x metabolismus $7 D019938
650    _2
$a poškození DNA $7 D004249
650    _2
$a deferoxamin $x farmakologie $7 D003676
650    _2
$a dioxygenasy $x antagonisté a inhibitory $x metabolismus $7 D049308
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a protein FOXO3 $x genetika $x metabolismus $7 D000071316
650    _2
$a lidé $7 D006801
650    _2
$a hydroxylace $7 D006900
650    _2
$a prolyl-4-hydroxylasy HIF $x metabolismus $7 D064799
650    _2
$a železo $7 D007501
650    _2
$a chelátory železa $x farmakologie $7 D007502
650    _2
$a kyseliny ketoglutarové $x farmakologie $7 D007656
650    _2
$a lymfom z plášťových buněk $x enzymologie $7 D020522
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a deficit železa $7 D000090463
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hlušičková Kapraľová, Katarína $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine and VAH, Salt Lake City, Utah. $7 xx0264741
700    1_
$a Raskova Kafkova, Leona $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Korinek, Vladimir $u Department of Cell and Developmental Biology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Divoky, Vladimir $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Prchal, Josef T., $u Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine and VAH, Salt Lake City, Utah. $d 1945- $7 xx0148595
700    1_
$a Lanikova, Lucie $u Department of Cell and Developmental Biology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine and VAH, Salt Lake City, Utah.
773    0_
$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 23, č. 11 (2019), s. 7785-7795
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31517438 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20220512081844 $b ABA008
999    __
$a ok $b bmc $g 1599686 $s 1116227
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 23 $c 11 $d 7785-7795 $e 20190913 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
GRA    __
$a NV16-31689A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options